Title | Type | ![]() |
H index | Total Docs. (2017) | Total Docs. (3years) | Total Refs. (2017) | Total Cites (3years) | Citable Docs. (3years) | Cites / Doc. (2years) | Ref. / Doc. (2017) | %Female (2017) | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
12 | Open Access Journal of Clinical Trials![]() | journal | 0.192 Q3 | 15 | 8 | 19 | 278 | 14 | 19 | 0.83 | 34.75 | 53.85 | ![]() |
11 | Fluoride - Quarterly Reports![]() | journal | 0.429 Q3 | 51 | 44 | 130 | 1362 | 174 | 118 | 1.15 | 30.95 | 50.00 | ![]() |
10 | Drug, Healthcare and Patient Safety![]() | journal | 0.481 Q3 | 30 | 11 | 54 | 470 | 102 | 54 | 1.07 | 42.73 | 26.00 | ![]() |
9 | Patient Preference and Adherence![]() | journal | 0.727 Q1 | 67 | 209 | 612 | 7561 | 1308 | 598 | 1.89 | 36.18 | 52.11 | ![]() |
8 | Biomarker Insights![]() | journal | 0.810 Q2 | 40 | 20 | 110 | 855 | 233 | 108 | 2.09 | 42.75 | 41.54 | ![]() |
7 | Core Evidence (discontinued)![]() | journal | 0.813 Q2 | 29 | 2 | 26 | 110 | 83 | 25 | 2.62 | 55.00 | 20.00 | ![]() |
6 | Drug Design, Development and Therapy![]() | journal | 0.974 Q1 | 94 | 323 | 1125 | 15037 | 3517 | 1099 | 3.05 | 46.55 | 40.37 | ![]() |
5 | International Journal of Nanomedicine![]() | journal | 1.225 Q1 | 179 | 622 | 1565 | 31106 | 8024 | 1543 | 4.65 | 50.01 | 42.70 | ![]() |
4 | Diabetes, Metabolic Syndrome and Obesity![]() | journal | 1.342 Q1 | 64 | 52 | 162 | 2713 | 620 | 160 | 3.20 | 52.17 | 42.45 | ![]() |
3 | Pharmacogenomics and Personalized Medicine![]() | journal | 1.353 Q1 | 37 | 31 | 66 | 1481 | 307 | 64 | 3.93 | 47.77 | 48.61 | ![]() |
2 | Infection and Drug Resistance![]() | journal | 1.603 Q1 | 65 | 59 | 107 | 2241 | 527 | 105 | 4.13 | 37.98 | 41.43 | ![]() |
1 | Nanotechnology, Science and Applications![]() | journal | 2.723 Q1 | 35 | 15 | 16 | 689 | 249 | 16 | 13.90 | 45.93 | 39.71 | ![]() |
Follow us on @ScimagoJR
Scimago Lab, Copyright 2007-2024. Data Source: Scopus®